Akebia Therapeutics and Keryx Biopharmaceuticals have completed the merger of their companies and are doing business under Akebia Therapeutics. Akebia is still traded on the Nasdaq Capital Market, while Keryx has been delisted, and its shareholders will receive shares in the merged company.
Akebia, Keryx Bio announce successful completion of merger
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.